Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

CONCORD BIOTECH LTD.

NSE : CONCORDBIOBSE : 543960ISIN CODE : INE338H01029Industry : Pharmaceuticals & DrugsHouse : Private

BSE1988.5590.05 (+4.74 %)

PREV CLOSE ( ) 1898.50

OPEN PRICE ( ) 1898.55

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 11304

TODAY'S LOW / HIGH ( )1898.50 2020.00

52 WK LOW / HIGH ( )1206 2658

NSE1991.2090.3 (+4.75 %)

PREV CLOSE( ) 1900.90

OPEN PRICE ( ) 1905.95

BID PRICE (QTY) 1991.20 (33)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 396104

TODAY'S LOW / HIGH( ) 1905.00 2019.00

52 WK LOW / HIGH ( )1205.45 2664

Select year

Particulars

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Mar 2020

Operational & Financial Ratios

Earnings Per Share (Rs)

29.45

22.95

183.92

246.92

177.66

CEPS(Rs)

34.57

28.11

21.50

25.08

18.18

DPS(Rs)

8.75

6.83

51.20

74.15

6.00

Book NAV/Share(Rs)

145.93

123.31

1159.94

1050.75

809.87

Tax Rate(%)

25.32

25.44

26.35

24.89

20.86

Margin Ratios

Core EBITDA Margin(%)

42.50

40.86

37.73

52.14

39.14

EBIT Margin(%)

40.88

38.89

33.56

49.89

41.07

Pre Tax Margin(%)

40.57

37.74

32.72

49.72

40.85

PAT Margin (%)

30.30

28.14

24.10

37.35

32.33

Cash Profit Margin (%)

35.57

34.47

30.99

41.73

36.40

Performance Ratios

ROA(%)

19.17

15.92

12.43

19.89

16.11

ROE(%)

21.88

20.06

16.64

26.55

21.94

ROCE(%)

29.13

26.70

21.66

32.96

26.23

Asset Turnover(x)

0.63

0.57

0.52

0.53

0.50

Sales/Fixed Asset(x)

1.25

1.13

1.06

1.31

1.68

Working Capital/Sales(x)

1.35

1.59

2.52

1.69

1.66

Efficiency Ratios

Fixed Capital/Sales(x)

0.80

0.89

0.94

0.76

0.60

Receivable days

111.87

108.22

102.99

104.76

128.17

Inventory Days

75.42

87.15

87.67

76.85

77.69

Payable days

149.88

179.16

144.10

192.42

200.10

Valuation Parameters

PER(x)

51.68

0.00

PCE(x)

44.02

0.00

Price/Book(x)

10.43

0.00

Yield(%)

0.57

EV/Net Sales(x)

15.62

0.00

-0.03

0.06

0.11

EV/Core EBITDA(x)

34.08

0.00

-0.06

0.10

0.23

EV/EBIT(x)

38.20

-0.01

-0.08

0.11

0.26

EV/CE(x)

10.36

0.00

-0.01

0.03

0.05

M Cap / Sales

15.66

0.00

Growth Ratio

Net Sales Growth(%)

19.20

19.67

15.56

20.42

0.00

Core EBITDA Growth(%)

21.38

29.11

-12.99

44.86

0.00

EBIT Growth(%)

25.30

36.18

-22.35

46.17

0.00

PAT Growth(%)

28.33

37.25

-25.53

39.02

0.00

EPS Growth(%)

28.33

-87.52

-25.51

38.99

0.00

Financial Stability Ratios

Total Debt/Equity(x)

0.00

0.02

0.05

0.09

0.06

Current Ratio(x)

6.30

3.79

1.84

2.57

2.41

Quick Ratio(x)

4.84

2.69

1.27

1.92

1.91

Interest Cover(x)

130.57

33.85

39.72

299.68

183.92

Total Debt/Mcap(x)

0.00